GlassScriptPhysician profile
Kynea Johnson
NPI 1215657978
$852.37
in general payments reported to CMS, 2019-2025
11 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.22 · 2023: $475 · 2024: $106 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $344.31 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $135.00 | 2022-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $103.14 | 2023-2025 | Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $80.32 | 2023-2025 | Perseris, Sublocade |
| Alkermes, INC. | $47.98 | 2023 | Aristada, Lybalvi |
| Bioxcel Therapeutics, INC. | $35.48 | 2023 | Igalmi |
| Vanda Pharmaceuticals INC. | $31.74 | 2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $19.32 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $16.82 | 2023 | Auvelity |
| Janssen Biotech, INC. | $13.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kynea Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.